Glenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. The company clarified that the letter won’t impact existing supplies or revenues. It also emphasized its commitment to compliance and noted no data integrity issues were found.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets